A comprehensive review on the potential therapeutic benefits of phosphodiesterase inhibitors on cardiovascular diseases

Publication date: October 2017
Source:Biomedicine & Pharmacotherapy, Volume 94
Author(s): Reza Shafiee-Nick, Amir R. Afshari, Seyed Hadi Mousavi, Abbasali Rafighdoust, Vahid Reza Askari, Hamid Mollazadeh, Sahar Fanoudi, Elmira Mohtashami, Vafa Baradaran Rahimi, Moein Mohebbi, Mohammad Mahdi Vahedi
Phosphodiesterases are a group of enzymes that hydrolyze cyclic nucleotides, which assume a key role in directing intracellular levels of the second messengers' cAMP and cGMP, and consequently cell function. The disclosure of 11 isoenzyme families and our expanded knowledge of their functions at the cell and molecular level stimulate the improvement of isoenzyme selective inhibitors for the treatment of various diseases, particularly cardiovascular diseases. Hence, future and new mechanistic investigations and carefully designed clinical trials could help reap additional benefits of natural/synthetic PDE inhibitors for cardiovascular disease in patients. This review has concentrated on the potential therapeutic benefits of phosphodiesterase inhibitors on cardiovascular diseases.



http://ift.tt/2u7q30j